Profund Advisors LLC lifted its stake in shares of  United Therapeutics Co. (NASDAQ:UTHR – Get Rating) by 0.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor  owned 6,584 shares of the biotechnology company’s stock after purchasing an additional 45 shares during the quarter. Profund Advisors LLC’s holdings in United Therapeutics were worth $1,831,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in UTHR. Wellington Management Group LLP boosted its position in shares of  United Therapeutics by 73.7% during the 1st quarter. Wellington Management Group LLP now owns 1,675,414 shares of the biotechnology company’s stock worth $300,585,000 after purchasing an additional 710,668 shares in the last quarter.  Vanguard Group Inc. boosted its position in shares of  United Therapeutics by 3.8% during the 3rd quarter. Vanguard Group Inc. now owns 4,411,616 shares of the biotechnology company’s stock worth $923,703,000 after purchasing an additional 163,542 shares in the last quarter.  Farallon Capital Management LLC boosted its position in shares of  United Therapeutics by 40.0% during the 3rd quarter. Farallon Capital Management LLC now owns 549,673 shares of the biotechnology company’s stock worth $115,091,000 after purchasing an additional 156,977 shares in the last quarter.  Kynam Capital Management LP bought a new position in shares of  United Therapeutics during the 3rd quarter worth about $31,618,000.  Finally, State Street Corp boosted its position in shares of  United Therapeutics by 7.2% during the 1st quarter. State Street Corp now owns 1,626,491 shares of the biotechnology company’s stock worth $291,809,000 after purchasing an additional 109,226 shares in the last quarter. Institutional investors own  95.63% of the company’s stock.

A number of equities analysts have recently issued reports on UTHR shares. LADENBURG THALM/SH SH cut their price objective on shares of United Therapeutics from $295.00 to $285.00 in a research report on Thursday, February 23rd. Morgan Stanley lowered their target price on shares of United Therapeutics from $320.00 to $316.00 and set an “overweight” rating on the stock in a report on Monday, April 10th. UBS Group lowered their target price on shares of United Therapeutics from $330.00 to $310.00 and set a “buy” rating on the stock in a report on Monday, April 10th. Argus upped their target price on shares of United Therapeutics from $250.00 to $300.00 and gave the stock a “buy” rating in a report on Wednesday, January 11th. Finally, JPMorgan Chase & Co. upped their target price on shares of United Therapeutics from $265.00 to $280.00 and gave the stock an “overweight” rating in a report on Thursday, February 23rd. Two equities research analysts have rated the stock with a sell rating and nine have issued  a buy rating to the stock. According to MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $290.27.

In other news, Director Louis W. Sullivan sold 700 shares of the firm’s stock in a transaction that occurred on Wednesday, February 1st. The shares were sold at an average price of $261.33, for a total transaction of $182,931.00. Following the completion of the sale, the director now owns 12,180 shares in the company, valued at approximately $3,182,999.40. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CEO Martine A. Rothblatt sold 8,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 19th. The shares were sold at an average price of $259.60, for a total transaction of $2,076,800.00. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $33,748. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Louis W. Sullivan sold 700 shares of the firm’s stock in a transaction that occurred on Wednesday, February 1st. The stock was sold at an average price of $261.33, for a total transaction of $182,931.00. Following the completion of the transaction, the director now directly owns 12,180 shares of the company’s stock, valued at $3,182,999.40. The disclosure for this sale can be found here. Insiders sold a total of 216,700 shares of company stock worth $51,675,651 in the last quarter. Insiders own  12.40% of the company’s stock.

NASDAQ:UTHR opened at $227.98 on Wednesday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 9.55 and a current ratio of 9.85. The firm has a market cap of $10.56 billion, a price-to-earnings ratio of 15.18 and a beta of 0.60. United Therapeutics Co. has a 52 week low of $173.21 and a 52 week high of $283.09. The firm has a 50-day moving average price of $234.13 and a two-hundred day moving average price of $248.33.

United Therapeutics (NASDAQ:UTHR – Get Rating) last posted its quarterly earnings data on Wednesday, February 22nd. The biotechnology company reported $2.67 EPS for the quarter, missing the consensus estimate of $4.12 by ($1.45). The firm had revenue of $491.50 million during the quarter, compared to analysts’ expectations of $519.20 million. United Therapeutics had a net margin of 37.56% and a return on equity of 16.30%. The company’s quarterly revenue was up 18.4% on a year-over-year basis. During the same quarter last year, the business posted $2.35 EPS.  On average, equities analysts expect that  United Therapeutics Co. will post 17.91 earnings per share for the current fiscal year.

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR – Get Rating).

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.